Blueprint Medicines (NASDAQ:BPMC) Downgraded to “Sell” Rating by StockNews.com

StockNews.com lowered shares of Blueprint Medicines (NASDAQ:BPMC) from a hold rating to a sell rating in a research note issued to investors on Friday.

Several other analysts have also commented on the company. JMP Securities reissued a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a report on Friday. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Piper Sandler raised their target price on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. HC Wainwright restated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday. Finally, Stephens restated an “overweight” rating and issued a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $123.83.

Blueprint Medicines Stock Down 1.3 %

Shares of BPMC opened at $93.94 on Friday. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. Blueprint Medicines has a 12 month low of $77.57 and a 12 month high of $121.90. The stock’s 50 day moving average is $99.61 and its two-hundred day moving average is $94.66. The firm has a market cap of $5.97 billion, a P/E ratio of -44.52 and a beta of 0.62.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. Analysts predict that Blueprint Medicines will post -3.63 earnings per share for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 15,161 shares of Blueprint Medicines stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the sale, the director now owns 152,396 shares in the company, valued at $16,691,933.88. The trade was a 9.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the sale, the chief executive officer now owns 149,378 shares in the company, valued at $16,467,430.72. This represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 49,851 shares of company stock worth $4,984,696 over the last quarter. 4.21% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Blueprint Medicines

A number of institutional investors have recently modified their holdings of BPMC. Pallas Capital Advisors LLC grew its stake in Blueprint Medicines by 3.2% during the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock worth $523,000 after purchasing an additional 176 shares in the last quarter. Torray Investment Partners LLC grew its stake in Blueprint Medicines by 1.1% during the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock worth $1,439,000 after purchasing an additional 186 shares in the last quarter. Franklin Resources Inc. grew its stake in Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after purchasing an additional 265 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in Blueprint Medicines by 4.4% during the 4th quarter. Ameritas Investment Partners Inc. now owns 6,652 shares of the biotechnology company’s stock worth $580,000 after purchasing an additional 283 shares in the last quarter. Finally, Pitcairn Co. grew its stake in Blueprint Medicines by 2.8% during the 4th quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company’s stock worth $925,000 after purchasing an additional 293 shares in the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.